An observational study in Neuro-PASC and Long COVID, sponsored by VA Office of Research and Development. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by VA Office of Research and Development · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · VA Office of Research and Development.
Among the 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 11th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →8 of the 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
VA Office of Research and Development · Sites in United States
Ages 18–89
VA Office of Research and Development · Sites in United States
Ages up to 80 · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 200 is above the median of 150 across 173 observational studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 60 across the 8 interventional studies, 200 across the 3 observational. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
5 of the studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06142253VA Office of Research and DevelopmentWater-based Activity to Enhance Recovery in Long COVID-19 | 2026-12-31 |
| NCT06291870VA Office of Research and DevelopmentPredictors of Post-COVID-19 Clinical and Cognitive Consequences | 2026-12-31 |
| NCT06086379VA Office of Research and DevelopmentCognitive Rehabilitation Therapy for COVID-19 | 2027-06-30 |
| NCT05373043VA Office of Research and DevelopmentLong-term COVID and Rehabilitation | 2027-10-31 |
| NCT05787379VA Office of Research and DevelopmentCare for Veterans Post-COVID-19 | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Mental health symptoms, including cognitive impairment ("brain fog"), following COVID-19 are of great concern to Veterans. This research seeks to advance understanding of the long-term effects of COVID-19 on neuropsychiatric and neurological functions, identifying clinically relevant biomarkers and directions for developing and testing therapeutic interventions. To accomplish these objectives the investigators are conducting a longitudinal study at two VA medical centers to: 1) assess and monitor cognitive function and psychiatric symptoms in Veterans post-COVID; 2) evaluate biomarkers of inflammation and signaling pathways associated with viral infection and neuropsychiatric function; and 3) integrate neuropsychiatric and neurological findings with biological data to identify biomarkers and clinical endpoints associated with disease progression or severity, as well as those for promoting brain repair and attenuating those symptoms.
The goal of this research project is to identify the neuroinflammatory mechanisms contributing to post-COVID cognitive deficits and neuropsychiatric symptoms [neuro-PASC (post-acute sequelae of SARS CoV-2 infection)]. This collaborative research effort will also characterize new or worsened mental health symptoms and genetic and environmental risk factors for the incidence and severity of post-COVID neuropsychiatric impairments. Aim 1 will monitor and evaluate cognitive injury and neuro-PASC symptoms and determine whether APOE genotype modulates severity of the cognitive injury and neuro-PASC symptoms. Cognitive functioning will be evaluated over time using neuropsychological measures assessing domains most relevant to PASC: learning and memory, attention/concentration, social cognition/emotions, and executive function; assessments will include standardized measures. Mental health symptoms known to be induced and exacerbated by inflammation and potentially developing as a result of COVID-19 will also be evaluated. APOE genotyping will be determined based on saliva or blood samples. Aim 2 will identify immune-related biomarkers associated with cognitive injury and neuro-PASC symptoms. Blood (plasma and cells) will be used to identify biomarkers associated with PASC progression or severity, promotion of brain repair, attenuation of symptoms. Plasma will be used for Olink proteomics, followed by confirmatory multiplex assays or enzyme-linked immunosorbent assays (ELISAs). The investigators will assess relationships among biomarkers and cognitive injury and neuro-PASC symptoms across APOE genotypes and contribute data and samples to the repository managed by Dr. Moorman (Co-Investigator). Aim 3 (exploratory aim; conducted in Portland only) will assess neuroimaging correlates of cognitive injury and neuro-PASC symptoms. Neuroimaging evaluations (i.e., whole brain voxel-based morphometry, diffusion-tensor imaging, resting-state connectivity, and task-based assessments) will be conducted at baseline and at 12 months to correlate magnetic resonance imaging (MRI) measures with symptoms of long COVID (e.g., cognitive impairment and neuropsychiatric symptoms) across APOE genotypes.
Veterans
Inclusion Criteria:
Eligible participants will:
Additionally, participants enrolled as part of the neuro-PASC group must also:
Exclusion Criteria:
Exclusion criteria for all groups:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants enrolled in the study will attend 4 study visits: 1) Screening, 2) Baseline, 3) 6-Month Follow-up, and 4) 12-Month Follow-up. At the Baseline, 6-Month, and 12-Month follow-up, participants will complete an online neuropsychological assessment, questionnaires, blood draw, and saliva collection
A subset (60) of Portland VA only participants will be provided with the opportunity to complete an MRI visit at baseline and the 12-month follow-up.
Fatigue Severity Scale (FSS)
A nine-item self-report questionnaire designed to assess fatigue as a symptom of a variety of different chronic conditions and disorders.
Time frame: Baseline, 6-Month, 12-Month
Prospective and Retrospective Memory Questionnaire (PRMQ)
A self-report measure of everyday memory, assessing prospective (the ability to remember to do things in the future) and retrospective memory.
Time frame: Baseline, 6-Month, 12-Month
Spatial Working Memory (SWM)
Online cognitive assessment requiring retention and manipulation of visuospatial information; measures executive functioning (i.e., strategy) and working memory.
Time frame: Baseline, 6-Months, 12-Months
Paired Associates Learning (PAL)
Online cognitive assessment measuring visual memory and new learning.
Time frame: Baseline, 6-Month, 12-Month
Stockings of Cambridge (SOC)
Online cognitive assessment measuring problem-solving strategies.
Time frame: Baseline, 6-Month, 12-Month
Delayed Matching Sample (DMS)
Online cognitive assessment measuring visual matching ability and short-term visual recognition memory.
Time frame: Baseline, 6-Month, 12-Month
Rapid Visual Information Processing (RVP)
Online cognitive assessment measuring sustained attention.
Time frame: Baseline, 6-Month, 12-Month
Apolipoprotein E (APOE) Genotyping
A genetic test that determines a person's inherited variations in the APOE gene. This gene plays a role in cholesterol metabolism and brain health. Blood and saliva samples will be used.
Time frame: Baseline, 6-Months, 12-Months
Long Covid Questionnaire
Self-report measure that assesses the continued presence of Long-COVID symptomology.
Time frame: Baseline
Delis-Kaplan Executive Functioning - Verbal Fluency (D-KEFS-VF)
Neuropsychological assessment measure of verbal behavioral productivity and cognitive flexibility.
Time frame: Baseline, 6-Months, 12-Months
Posttraumatic Stress Disorder Checklist - Civilian Version (PCL-C)
A standardized self-report rating scale for PTSD comprising 17 items that correspond to the key symptoms of PTSD.
Time frame: Baseline, 6-Month, 12-Month
Patient Health Questionnaire-9 (PHQ-9)
Self-report questionnaire objectifying and assessing degree of depression severity.
Time frame: Baseline, 6-Months, 12-Months
Generalized Anxiety Disorder-7 (GAD-7)
A self-reported questionnaire used to assess the severity of anxiety symptoms.
Time frame: Baseline, 6-Month, 12-Month
Biomarkers
Obtained from collected blood samples and saliva, biomarkers (including viral variants, genetic susceptibility, inflammatory markers, diagnostic markers, etc.) associated with specific symptoms of post-COVID conditions will be identified.
Time frame: Baseline, 6-Months, 12-Months
Neuroimaging
To detect pathological and restorative changes in the brain of COVID-19 survivors, neuroimaging evaluations will correlate magnetic resonance imaging (MRI) measures with symptoms of neuro-PASC.
Time frame: Baseline, 12-Months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Mar 2028, 37 months after the start.
Of 97 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 37 months is above that.
Counting every sponsor, half of 104 studies reached it within 26 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
VA Office of Research and Development →